Close

UPDATE: Baird Starts Decibel Therapeutics Inc (DBTX) at Outperform

October 21, 2021 4:12 PM EDT
Get Alerts DBTX Hot Sheet
Price: $3.50 --0%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 5 | Down: 2 | New: 19
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - October 21, 2021 4:20 PM EDT)

Baird analyst Jack Allen initiates coverage on Decibel Therapeutics Inc (NASDAQ: DBTX) with a Outperform rating and a price target of $21.00.

The analyst comments "Decibel's diverse otology pipeline provides a number of ways to win. Starting with DB-OTO, the lead gene therapy, here we are encouraged by the preclinical data and believe that congenital OTOF deficiency is an indication well suited for gene therapy. Shifting gears to DB-020, Decibel's otoprotective therapy, we view this program as fairly derisked given Fennec's positive STS data. With clinical readouts expected over the course of the next 12-18months, we believe positive data from either one of these programs could result in significant appreciation of shares."

For an analyst ratings summary and ratings history on Decibel Therapeutics Inc click here. For more ratings news on Decibel Therapeutics Inc click here.

Shares of Decibel Therapeutics Inc closed at $7.47 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird